Introduction
Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently recognized neurodegenerative condition defined by the accumulation of phosphorylated TDP-43 protein in limbic brain regions, often co-occurring with Alzheimer's disease pathology but representing a distinct clinicopathological entity. [@nelson2019][@buciuc2023]
Pathogenesis Flowchart
Mermaid diagram (expand to render)
Key Pathological Features
- TDP-43 Pathology: Phosphorylated, ubiquitinated, and truncated TDP-43 inclusions
- Limbic Predominance: Primary involvement of amygdala, [hippocampus](/brain-regions/hippocampus), and entorhinal [cortex](/brain-regions/cortex)
- Age Association: Typically onset after age 80
- Clinical Phenotype: Amnestic syndrome resembling AD but with distinct progression
Clinical Presentation
Memory Impairment
LATE primarily affects episodic memory, with semantic memory decline also common. Patients present with gradual memory loss that may be initially indistinguishable from Alzheimer's disease.
Disease Progression
The progression of LATE is generally slower than typical Alzheimer's disease, with survival times often exceeding 5-7 years from symptom onset.
Relationship to Alzheimer's Disease
LATE frequently co-exists with Alzheimer's disease (AD) pathology, and the combination of both pathologies results in more severe cognitive impairment than either alone. However, LATE can also occur in the absence of significant amyloid or [tau](/proteins/tau) pathology. [@robinson2022]
LATE-AD Amnestic Dementia Syndrome
The co-occurrence of LATE and AD pathology represents a common mixed dementia phenotype, particularly in oldest-old individuals.
Neuropathology
TDP-43 Proteinopathy
LATE is characterized by neuronal and glial inclusions containing phosphorylated TDP-43, primarily affecting the limbic system and adjacent temporal lobe structures.
Distribution Pattern
The staging of LATE follows a predictable pattern: beginning in the amygdala, progressing to hippocampus, then to [entorhinal cortex](/brain-regions/entorhinal-cortex) and inferior temporal gyrus.
Biomarkers
MRI Findings
Hippocampal atrophy on structural MRI is a key finding, though pattern may differ from typical AD.
CSF and Blood Biomarkers
Emerging evidence supports CSF and blood biomarkers for TDP-43 pathology, though these are not yet standardized for clinical use.
Epidemiology
LATE is now recognized as one of the most common neurodegenerative pathologies in older adults, affecting approximately 10-25% of individuals over age 80. [@meehan2024] Autopsy studies consistently demonstrate that TDP-43 pathology in the limbic system is present in a substantial proportion of cognitively impaired elderly individuals, often alongside Alzheimer's disease changes.
Prevalence by Age
- Age 70-79: Approximately 5-10% prevalence
- Age 80-89: Approximately 15-20% prevalence
- Age 90+: Up to 25-30% prevalence in some cohorts
The age-dependent increase in prevalence distinguishes LATE from many other neurodegenerative conditions, with the "oldest-old" (those over 90) showing the highest burden. [@kaufman2023]
Sex Distribution
Current evidence suggests a slight female predominance in LATE, though this may reflect survival bias and the greater longevity of women in affected age cohorts. [@agrawal2024]
Risk Factors
Genetic Risk Factors
Apolipoprotein E (APOE)
The [APOE](/proteins/apoe-protein) ε4 allele represents the strongest known genetic risk factor for LATE, with carriers showing approximately 2-3 fold increased risk. [@yang2022] Interestingly, the [APOE](/proteins/apoe-protein) ε2 allele may confer protection against LATE pathology.
GRN (Progranulin)
Loss-of-function mutations in the [GRN](/genes/grn) gene cause familial frontotemporal dementia and are associated with TDP-43 pathology. Common genetic variants near GRN may influence LATE risk. [@chenplotkin2022]
Other Genetic Loci
Genome-wide association studies have identified several additional risk loci, including variants in:
- TMEM106B: Associated with TDP-43 pathology in both FTLD and LATE [@zhang2023]
- ABI3: Emerging genetic risk factor
- PLCΑ2: Additional susceptibility locus
Non-Genetic Risk Factors
Vascular Disease
Cerebrovascular disease, including small vessel disease and white matter hyperintensities, appears to increase LATE risk. The presence of vascular pathology may interact with TDP-43 to accelerate cognitive decline.
Traumatic Brain Injury
History of traumatic brain injury has been suggested as a potential risk factor, though evidence remains preliminary.
Education and Cognitive Reserve
Higher education and greater cognitive reserve may provide some protection, potentially by delaying the clinical manifestation of LATE pathology.
Diagnostic Criteria
Clinical Diagnostic Framework
The 2023 consensus criteria for LATE staging establish a clinical-pathological framework: [@nelson2023]
Stage 1 (LATE Limbic Stage)
- Isolated memory impairment or mild cognitive impairment
- Predominant involvement of amygdala
- Often asymptomatic or minimally symptomatic
Stage 2 (LATE Amygdala-Hippocampal Stage)
- Progressive memory impairment
-扩展 to include hippocampus
- Clinical symptoms more apparent
Stage 3 (LATE Isocortical Stage)
- Severe memory and executive dysfunction
- Involvement of entorhinal cortex and neocortex
- Often meets criteria for dementia
Biomarker-Based Diagnosis
Neuroimaging
- MRI: Patterns of limbic atrophy, particularly in amygdala and hippocampus, may suggest LATE
- PET: While amyloid and [tau](/proteins/tau) ligands are negative, emerging TDP-43 PET ligands are in development
- Structural MRI can help differentiate LATE from typical AD based on atrophy patterns
CSF Biomarkers
- p-tau181 and [p-tau217](/biomarkers/p-tau-217): Lower levels in LATE compared to AD
- Total [tau](/proteins/tau): Intermediate levels between AD and controls
- [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Elevated in LATE but less than in AD
- p-TDP-43: Emerging CSF marker for TDP-43 pathology [@fergiusdottir2024]
Blood Biomarkers
Plasma p-tau181 and p-tau217 show promise for distinguishing LATE from AD, with lower levels in LATE compared to pure AD cases.
Differential Diagnosis
LATE must be distinguished from:
- [Alzheimer's Disease](/diseases/alzheimers-disease) (pure AD has higher amyloid and tau burden)
- [Frontotemporal Lobar Degeneration (FTLD)](/diseases/frontotemporal-lobar-degeneration))))) (FTLD typically presents with earlier onset and more focal behavioral or language symptoms)
- [Primary Age-Related Tauopathy (PART)](/diseases/primary-age-related-tauopathy) (PART lacks TDP-43 pathology)
- [Parkinson's Disease](/diseases/parkinsons-disease) and related disorders
Treatment Approaches
Current Management
There are no disease-modifying treatments specifically approved for LATE. Current management focuses on:
Symptomatic Treatment
- Cognitive enhancers: [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) ([donepezil](/therapeutics/donepezil), [rivastigmine](/entities/rivastigmine), galantamine) may provide modest benefit in LATE patients, particularly those with comorbid AD pathology
- Memantine: May offer symptomatic benefit in some patients
Non-Pharmacological Interventions
- Cognitive stimulation therapy: Structured activities to maintain cognitive function
- Physical exercise: Regular aerobic activity may help slow progression
- Social engagement: Maintaining social connections is important for quality of life
- Sleep hygiene: Proper sleep may support TDP-43 clearance mechanisms
Emerging Therapeutic Strategies
TDP-43-Targeted Approaches
- Antisense oligonucleotides (ASOs): Targeting TDP-43 expression is under investigation, particularly for LATE-FTLD overlap cases
- Small molecule aggregation inhibitors: Compounds that prevent TDP-43 misfolding and aggregation are in preclinical development [@liu2024]
- [Autophagy](/entities/autophagy) enhancers: Promoting clearance of misfolded TDP-43 proteins
Anti-Inflammatory Strategies
Given the role of neuroinflammation in LATE pathogenesis:
- Microglial modulators: Targeting abnormal microglial activation
- [NLRP3](/proteins/nlrp3) inhibitors: Reducing inflammasome-driven inflammation
Neuroprotective Approaches
- Synaptic protectors: Maintaining synaptic function despite pathology
- Neurotrophic factors: Supporting neuronal survival
Clinical Trials
Current Trial Landscape
As of 2024, no large-scale Phase 3 trials are specifically targeting LATE. However, several trials for related conditions may provide insights:
Active or Recent Studies
- GRN-related trials: Several trials are targeting progranulin deficiency in FTLD-TDP, with potential implications for LATE
- TDP-43 aggregation inhibitors: Early-phase studies in ALS/FTLD may yield agents applicable to LATE
- Anti-tau immunotherapies: While targeting tau, these may benefit LATE patients with comorbid AD pathology
Biomarker Development Trials
- Studies validating CSF and blood biomarkers for TDP-43 pathology
- Imaging trials developing TDP-43-specific PET ligands
Challenges in LATE Clinical Trials
Diagnostic uncertainty: Clinical diagnosis remains challenging without definitive biomarkers
Heterogeneity: Variable comorbidity with AD and other pathologies
Age and comorbidities: The advanced age of LATE patients complicates trial participation
Endpoint selection: Traditional cognitive measures may not capture LATE-specific outcomesFuture Research Directions
Biomarker Development
Priority Areas
- Blood-based p-TDP-43 assays: Highly sensitive tests for detecting TDP-43 pathology in vivo
- TDP-43 PET ligands: Enabling visualization of TDP-43 burden in living patients
- Fluid biomarker panels: Combining multiple markers for accurate LATE diagnosis
Mechanistic Understanding
Key Research Questions
- What triggers TDP-43 mislocalization and aggregation in aging?
- Why is the limbic system preferentially affected?
- How does LATE interact with AD pathology to produce more severe cognitive decline?
- What determines whether an individual develops LATE versus pure AD?
Therapeutic Development
Promising Approaches
- Gene therapy: Delivering factors that enhance TDP-43 clearance
- Cellular reprogramming: Replacing affected [neurons](/entities/neurons) with healthy cells
- Precision medicine: Developing genotype-stratified treatments based on genetic risk factors
Epidemiological Studies
Needed Research
- Longitudinal studies tracking LATE progression from preclinical to clinical stages
- Population-based prevalence studies in diverse ethnic groups
- Studies examining modifiable risk factors
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Frontotemporal Lobar Degeneration (FTLD)](/diseases/frontotemporal-lobar-degeneration)
- [Primary Age-Related Tauopathy (PART)](/diseases/primary-age-related-tauopathy)
- [GRN Gene](/proteins/grn-protein)
- [TDP-43 Biomarkers](/biomarkers/tdp-43)
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data
References
[Nelson et al., LATE-NC: A New Age-Related Disease (Brain, 2019) (2019)](https://doi.org/10.1093/brain/awz099)
[Buciuc et al., LATE Clinical Features (Neurology, 2023) (2023)](https://doi.org/10.1212/WNL.0000000000207415)
[Robinson et al., LATE and AD Co-Pathology (Acta Neuropathol, 2022) (2022)](https://doi.org/10.1007/s00401-022-02396-4)
[Meehan et al., LATE Prevalence in Community-Based Cohorts (Acta Neuropathol, 2024) (2024)](https://doi.org/10.1007/s00401-024-02644-5)
[Kaufman et al., LATE in the Oldest-Old (Neurology, 2023) (2023)](https://doi.org/10.1212/WNL.0000000000207401)
[Agrawal et al., Sex Differences in LATE Pathology (J Neuropathol Exp Neurol, 2024) (2024)](https://doi.org/10.1093/jnen/nlae034)
[Yang et al., APOE and LATE Risk (Neurology, 2022) (2022)](https://doi.org/10.1212/WNL.0000000000201503)
[Chen-Plotkin et al., TMEM106B and TDP-43 Pathology (Brain, 2022) (2022)](https://doi.org/10.1093/brain/awab439)
[Zhang et al., TMEM106B Genetic Variants in LATE (Acta Neuropathol Commun, 2023) (2023)](https://doi.org/10.1186/s40478-023-01567-0)
[Nelson et al., LATE Consensus Diagnostic Criteria 2023 (Brain, 2023) (2023)](https://doi.org/10.1093/brain/awad238)
[Fergiusdottir et al., CSF p-TDP-43 as LATE Biomarker (Neurology, 2024) (2024)](https://doi.org/10.1212/WNL.0000000000209352)
[Liu et al., TDP-43 Aggregation Inhibitors (Nat Neurosci, 2024) (2024)](https://doi.org/10.1038/s41593-024-01628-0)